In the second part of his Pharma Commerce video interview, John Stanford, Incubate’s executive director, points out how uneven Medicare negotiation timelines between small molecules and biologics are influencing R&D and venture funding decisions, according to biotech investors advocating for legislative changes.
In the first part of his Pharma Commerce video interview, John Stanford, Incubate’s executive director, explains how third round of CMS drug selections brings physician-administered medicines under price controls for the first time, intensifying debate over provider reimbursement and investment in small-molecule therapies.
In the final part of his Pharma Commerce video interview, Dan Chancellor, Norstella’s vice president of thought leadership, shares that companies facing the largest revenue gaps from looming patent expirations—including Bristol Myers Squibb—could be poised for increased dealmaking as they look to rebuild growth pipelines.
Pharma’s $372B M&A surge fights a $300B patent cliff, with firms relying on early-stage assets and Chinese innovation to fill gaps by 2030.
In the second part of his Pharma Commerce video interview, Dan Chancellor, Norstella’s vice president of thought leadership, suggests that 2026 pharma M&A may fall short of last year’s $220 billion total—potentially featuring fewer but larger, high-value acquisitions driven by competitive bidding.
In the first part of his Pharma Commerce video interview, Dan Chancellor, Norstella’s vice president of thought leadership, explains that despite a looming loss of exclusivity affecting up to $300 billion in drug sales by 2032, pharma dealmaking is expected to remain steady in 2026, as companies pursue acquisitions to close persistent portfolio growth gaps.
In the final part of her Pharma Commerce video interview, Valerie Bandy, PharmD, Tecsys’ vice president of pharmacy solutions, shares why short-term AI use cases—such as demand sensing and shortage risk detection—are delivering the most value in pharmacy supply chains.
In the second part of her Pharma Commerce video interview, Valerie Bandy, PharmD, Tecsys’ vice president of pharmacy solutions, points out that shortages remain the top disruption driver, revealing fragmented forecasting, limited enterprise visibility, and poor cross-system integration that keep hospitals stuck in reactive mode instead of proactive planning.
In the first part of her Pharma Commerce video interview, Valerie Bandy, PharmD, Tecsys’ vice president of pharmacy solutions, explains why health systems lack real-time pharmacy inventory visibility, driving reactive decisions, higher costs, and increased vulnerability to shortages and disruptions.
In the final part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, outlines how real-time AI signal sharing across supply chain partners can help pharma companies anticipate demand shifts, reduce shortages, and respond faster to pandemics and geopolitical disruptions.
In the third part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, explains why independent verification, validation, and human decision-making must stay central, as AI accelerates data processing and operational workflows across pharma supply chains.
In the second part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, notes that in order to reduce risk and accelerate adoption, supply chain leaders can begin applying AI to machine-generated data—such as IoT sensor outputs—where insights improve performance without raising concerns about data ownership, security, or competitive exposure.
In the first part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, explains how pharma leaders can detect early warning signs beyond their own silos and adapt before disruption becomes unavoidable.
In the final part of his Pharma Commerce video interview, Hari Kiran Chereddi, CEO of HRV Pharma, explains how federated intelligence, audit-ready data systems, and a culture of compliance are enabling scalable transparency across decentralized pharmaceutical manufacturing networks.
In the second part of his Pharma Commerce video interview, Hari Kiran Chereddi, CEO of HRV Pharma, describes how AI-driven orchestration, real-time data integration, and federated learning are reshaping pharmaceutical supply chains for faster, safer, and more agile operations.
Artificial intelligence is helping pharma teams uncover critical safety signals faster, lower costs, and shift pharmacovigilance from compliance to competitive advantage.
In the fourth part of his Pharma Commerce video interview, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, outlines the financial pressures that make sustained safety net protections a healthcare imperative.
In the second part of his Pharma Commerce video interview, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, describes how rising healthcare and living costs are expanding financial hardship beyond traditional eligibility thresholds, while safety-net resources shrink and demand accelerates.
In the third part of his Pharma Commerce video interview, Franco Stevanato, CEO of Stevanato Group, shares how automatic contract adjustments tied to labor, energy, and inflation—combined with the critical role of supply reliability—allow the company to pass through limited surcharges while maintaining strong client relationships.
In the second part of his Pharma Commerce video interview, Franco Stevanato, CEO of Stevanato Group, describes how from FDA validation to dual-site redundancy and reshoring momentum, the expansion of US capacity is a competitive advantage for pharma clients navigating increasingly complex global supply chains.
In the first part of his Pharma Commerce video interview, Franco Stevanato, CEO of Stevanato Group, explains how near-term tariff pressures are creating short-term headwinds while accelerating longer-term investment in regional manufacturing footprints—especially in the US.
In the final part of his Pharma Commerce video interview, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, points out that from biosimilars and site-of-care shifts to AI, value-based reimbursement, and potential legislative action, market deflators—not simple cost shifting—will determine whether affordability improves across employer-sponsored plans, Medicaid, and Medicare.
In the third part of his Pharma Commerce video interview, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, explains as medical inflation persists and benefit designs strain under rising drug spend—especially GLP-1s—employers are reaching the limits of what they can absorb, accelerating cost-shifting and fragmenting how employees pay for care.
In the second part of his Pharma Commerce video interview, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, points out that a Medicaid spending tightens and ACA subsidies lapse, reduced public coverage is driving spillover effects—shifting costs to hospitals, employers, and commercial drug pricing in an increasingly interconnected healthcare market.
In the first part of his Pharma Commerce video interview, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, discusses how from GLP-1 adoption to specialty drugs, behavioral health utilization, and hospital consolidation, multiple forces are reshaping employer-sponsored healthcare costs—and pushing premiums and cost-sharing higher.
In the final part of his Pharma Commerce video interview, Arthur Axelrad, co-founder and CEO of Dispatch Science, explains how outdated, batch-based communication between shippers and carriers is undermining last-mile resilience—and why APIs, cloud platforms, and real-time connectivity are essential to improving transparency, safety, and speed in healthcare logistics.
In the final part of her Pharma Commerce video interview, Tina Martinez, vice president and head of global products and solutions at Cencora, explains how streamlining clinical supply services, reducing fragmentation, and piloting data-driven tools like real-time adherence tracking are translating innovation into quantifiable efficiency, visibility, and commercial impact for manufacturers worldwide.
In the second part of his Pharma Commerce video interview, Arthur Axelrad, co-founder and CEO of Dispatch Science, outlines how lapses in digital verification, real-time tracking, and chain-of-custody controls—from pickup through delivery—create security, compliance, and temperature-risk challenges in the final mile of medical logistics.
In the second part of her Pharma Commerce video interview, Tina Martinez, vice president and head of global products and solutions at Cencora, outlines a customer-first approach to partnering with pharmaceutical manufacturers—centered on active listening, early problem validation, and iterative piloting—to co-develop scalable solutions that support late-stage clinical programs through commercial launch.
In the first part of his Pharma Commerce video interview, Arthur Axelrad, co-founder and CEO of Dispatch Science, discusses growing concerns around cargo theft and fraud in healthcare logistics—and how enhanced security features and platform innovation are helping manufacturers protect chain of custody and compliance.
